13 citations
,
January 2015 in “Steroids” The study created a model to help design new inhibitors for steroidal 5α-reductase enzymes.
40 citations
,
December 2016 in “Journal of Dermatological Treatment” JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.
3 citations
,
September 2008 in “Current signal transduction therapy” Drugs that block GSK-3 show promise for treating various diseases.
February 2025 in “PubMed” CS12192 effectively treats alopecia areata with better safety than current options.
100 citations
,
March 2006 in “Journal of biological chemistry/The Journal of biological chemistry” Cystatin M/E strongly inhibits cathepsin V and cathepsin L, important for skin formation.
7 citations
,
January 2004 in “Drugs of today” 5alpha-reductase inhibitors help treat hair loss and prostate issues but may cause sexual side effects.
5α-reductase inhibitors help treat prostate enlargement and hair loss but may cause side effects, requiring careful use.
5α-reductase inhibitors effectively treat enlarged prostate and hair loss but require careful use due to possible side effects.
July 2025 in “Saudi Journal of Medicine and Public Health” 5α-reductase inhibitors effectively treat enlarged prostate and hair loss but require careful use due to possible side effects.
69 citations
,
December 2005 in “Nature Clinical Practice Endocrinology & Metabolism” Blocking the enzyme 11β-HSD1 might help treat obesity and metabolic issues.
3 citations
,
March 2020 in “The Journal of Urology” Older patients sticking to their prostate medication saw lasting health benefits.
3 citations
,
December 2000 in “PubMed” CS-891 may effectively treat hair loss by blocking enzymes in hair follicles.
February 2026 in “Postgraduate Medicine” 5-alpha reductase inhibitors slightly increase depression risk, but the risk varies based on the control group used.
August 2025 in “medRxiv (Cold Spring Harbor Laboratory)” 5-alpha reductase inhibitors may increase depression risk by 31%, but results vary based on comparison groups.
1 citations
,
March 2004 in “Journal of the American Academy of Dermatology” ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.
44 citations
,
February 2009 in “Pain” Progesterone reduces spinal reflex activity by increasing certain GABA(A) receptor subtypes.
60 citations
,
December 2013 in “PLoS ONE” EETs can delay seizures by affecting GABA activity, offering potential new treatments for seizures.
1 citations
,
November 2022 in “Journal of Investigative Dermatology” ALRN-6924 may prevent hair loss caused by chemotherapy.
21 citations
,
November 2015 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” There is no cure for alopecia areata, but treatments like JAK inhibitors show promise.
4 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
49 citations
,
February 2022 in “Drug Design Development and Therapy” Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
24 citations
,
February 2007 in “Hormone and metabolic research” The substance MK386 effectively blocked testosterone conversion and reduced cell growth in certain skin cells, but inhibiting 5α-reductase alone may not greatly improve acne.
September 2025 in “International Journal of Molecular Sciences” Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.
19 citations
,
August 2023 in “Journal of Dermatological Treatment” Abrocitinib may effectively treat stubborn alopecia universalis.
1 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
2 citations
,
May 2025 in “Journal of Clinical Medicine” Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.
February 2026 in “International Journal of Dermatology” Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.
June 2026 in “Frontiers in Immunology” Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.
September 2025 in “Asian journal of pediatric dermatology.” Abrocitinib helped a 14-year-old girl with severe alopecia areata regrow her hair significantly.
4 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Abrocitinib may help treat alopecia areata effectively with mild side effects.